Mylan has appointed John Thievon as president of its subsidiary Dey Pharma, whose products include Perforomist formoterol inhalation solution and the EasyVent valved holding chamber for MDIs. Thievon was most recently President and CEO of Middlebrook Pharmaceuticals and was previously Executive VP of Commercial Operations at Adams Respiratory Therapeutics.
“I am thrilled to be joining Mylan as Dey’s new president. I am excited about the potential of Dey’s existing product portfolio and the introduction of new products. The momentum behind this business is a result of impressive execution by the strong team already in place at Dey and I look forward to working alongside this team to maximize Dey’s growth potential,” said Thievon.
Mylan President Heather Bresch commented on the appointment: “I am extremely pleased to welcome John as our new leader of Mylan’s specialty business. John’s extensive experience growing a branded pharmaceutical business from the ground up and proven track record launching highly successful pharmaceutical brands, like Mucinex, is invaluable as we continue to build on our specialty business. Dey has been and continues to be a very valuable asset and important growth driver for Mylan, evidenced by the strong performance of this business. John’s appointment demonstrates our continued commitment to invest in Dey and strengthen what we have in place in order to support the continued success of this business into the future.”
Read the Mylan press release.
